IMiPACT

The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI is a joint undertaking between the European Commission and the pharmaceutical industry association EFPIA that supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

Starting 2014 in collaboration with the Centre for the Advancement of Sustainable Medical Innovation (CASMI), we aimed to create a method to assess the impact of IMI projects, going over and beyond bibliometric success (e.g. papers and patents) to real-world impact. In this project, we reviewed IMI project portfolios to define critical qualitative and quantitative success metrics (outcomes) that are meaningful to all participating stakeholders.

An important area for development was ensuring that key stakeholders are as fully engaged in IMI projects as possible. A stakeholder platform of influential stakeholders was proposed to review and define the outputs and outcomes of IMI projects and encourage early engagements in those projects, with a view to enabling systematic change. This stakeholder platform would enablee continuation of project outcomes beyond the lifetime of the funded project. New IMI projects will build upon the results of IMiPACT.

Client:
The Innovative Medicines Initiative (IMI)

Date of completion:
2014